Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Nijat Khanmammadov"'
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-8 (2023)
Abstract The purpose of the study was to assess the prognosis of HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression and investigate the predictors of complete response. HER2-positive metastatic breast cancer p
Externí odkaz:
https://doaj.org/article/092ef7515ff9489695537e85f2c1cffe
Autor:
Izzet Dogan, Nijat Khanmammadov, Melin Aydan Ahmed, Anıl Yıldız, Pinar Saip, Adnan Aydiner, Sezai Vatansever
Publikováno v:
Clinical Cancer Investigation Journal. 11:25-29
Autor:
Izzet Dogan, Nijat Khanmammadov, Melin Aydan Ahmed, Anıl Yıldız, Pinar Saip, Adnan Aydiner, Sezai Vatansever
Publikováno v:
Clinical Cancer Investigation Journal. 11:5-9
Autor:
Mustafa Gürbüz, Saadettin Kiliçkap, Ahmet Bilici, Nuri Karadurmuş, Ahmet Sezer, Mehmet Ali Nahit Şendur, Semra Paydaş, Mehmet Artaç, Perran Fulden Yumuk, Pinar Gürsoy, Mükremin Uysal, Hasan Şenol Coşkun, Ali Murat Tatli, Fatih Selçukbiricik, Umut Dişel, Elif Berna Köksoy, Deniz Can Güven, Muzaffer Uğrakli, Erman Akkuş, Şebnem Yücel, Cihan Erol, Serdar Karakaya, Teoman Şakalar, Nijat Khanmammadov, Nail Paksoy, Ahmet Demirkazik
Publikováno v:
Medicine. 101(50)
Crizotinib is a multikinase inhibitor, effective in non-small cell lung cancer (NSCLC) harboring mesenchymal-epidermal transition (MET) alterations. Although small prospective studies showed efficacy and safety of crizotinib in NSCLC with MET alterat
Publikováno v:
Cancer Research. 81:PS14-25
Background: Breast cancer is rare in men. The prognosis of male breast cancer (MBC) is poor than female breast cancer. The study aims to evaluate the clinical features and prognosis in metastatic male breast cancer (mMBC). Method: The data of 28 pati
Publikováno v:
Cancer Research. 81:PS10-44
Background: Trastuzumab has been used for HER2 positive breast cancer treatment for more than 20 years. The ratio of HER2 overexpression in breast cancer patients is about 20%. In this study, we aim to evaluate the prognosis of HER2 positive breast c
Autor:
Nail Paksoy, Nijat Khanmammadov, İzzet Doğan, Ferhat Ferhatoğlu, Melin Aydan Ahmed, Sule Karaman, Adnan Aydiner
Publikováno v:
Medicine. 102:e32866
Autor:
Nijat Khanmammadov, Mehmet Zorlu, Omer Faruk Ozer, Cumali Karatoprak, Muharrem Kıskaç, Mustafa Çakırca
Publikováno v:
Revista da Associação Médica Brasileira v.68 n.2 2022
Revista da Associação Médica Brasileira
Associação Médica Brasileira (AMB)
instacron:AMB
Revista da Associação Médica Brasileira, Volume: 68, Issue: 2, Pages: 147-151, Published: 28 FEB 2022
Revista da Associação Médica Brasileira
Associação Médica Brasileira (AMB)
instacron:AMB
Revista da Associação Médica Brasileira, Volume: 68, Issue: 2, Pages: 147-151, Published: 28 FEB 2022
SUMMARY OBJECTIVE: Beta-thalassemia minor is a blood disease caused by a hereditary decrease in beta-globin synthesis, frequently leading to hypochromic microcytic anemia. Formerly called endothelial cell-specific molecule 1, endocan is a proteoglyca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::deaa6ad16ef1d26935e9908c0f2ca7fa
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302022000200147
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302022000200147
Autor:
Nail Paksoy, Ferhat Ferhatoglu, İzzet Dogan, Nijat Khanmammadov, Ayca Iribas Celik, Zafer Gulbas, Mert Başaran
Publikováno v:
Medicine. 101:e32213
Autor:
Nail, Paksoy, Nijat, Khanmammadov, İzzet, Doğan, Ferhat, Ferhatoğlu, Anil, Yildiz, Naziye, Ak, Adnan, Aydiner
Publikováno v:
Medicine. 101:e31726
Epithelial Ovarian cancer (EOC) is the most lethal gynecologic cancer worldwide. Carboplatin (CP) is the main chemotherapeutic agent in the treatment of ovarian cancer. However, the development of a hypersensitivity reaction (HSR) in 10% to 15% of pa